Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ known ✓ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 0.44 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | DGKA | P23743 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29396916 | 1.00 | MGLL (0.50) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Hydrochloric Acid SCHEMBL421821 | 1.00 | MGLL (0.50) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Hydrochloric Acid SCHEMBL28736736 | 0.99 | MGLL (0.49) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| SCHEMBL441411 | 0.99 | MGLL (0.51) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| SCHEMBL30180550 | 0.99 | MGLL (0.51) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| SCHEMBL28968652 | 0.99 | MGLL (0.51) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| SCHEMBL747314 | 0.99 | MGLL (0.51) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Water SCHEMBL6549699 | 0.98 | MGLL (0.50) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Hydrochloric Acid SCHEMBL18209372 | 0.93 | DGKA (0.49) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Hydrochloric Acid SCHEMBL888281 | 0.93 | DGKA (0.49) | MGLLEPHX2DGKAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292106-B1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | BAYER ANIMAL HEALTH GMBH (DE) | 2021-10-27 | — | — | EP | claimed |
| US-10479768-B2 | Process for the preparation of amphiphilic imidazolinium compounds | BAYER ANIMAL HEALTH GMBH (DE) | 2019-11-19 | — | — | US | claimed |
| US-20180148415-A1 | IMPROVED PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2018-05-31 | — | — | US | claimed |
| EP-3292106-A1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | Bayer Animal Health GmbH (DE) | 2018-03-14 | — | — | EP | claimed |
| WO-2016177693-A1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-11-10 | — | — | WO | claimed |
| US-9089537-B2 | Subunit vaccines for herpes viruses and methods of use | THE TRUSTEES OF THE UNIVERSITY OF PENNSLYVANIA (US) | 2015-07-28 | — | — | US | claimed |
| US-20030229040-A1 | Cationic liposomal delivery system and therapeutic use thereof | GEORGETOWN UNIVERSITY | 2003-12-11 | — | — | US | claimed |
| US-20030166601-A1 | Novel colloid synthetic vectors for gene therapy | WOODLE MARTIN C (US) | 2003-09-04 | — | — | US | claimed |
| US-6559129-B1 | Administering a radiosensitizing effective amount of a cationic liposomal formulation comprising at least one cationic lipid to radiosensitize raf oncogene expressing tumor tissue in a subject in need of such treatment | GEORGETOWN UNIVERSITY | 2003-05-06 | — | — | US | claimed |
| EP-3292106-B1 | PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | BAYER ANIMAL HEALTH GMBH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-10479768-B2 | Process for the preparation of amphiphilic imidazolinium compounds | BAYER ANIMAL HEALTH GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-10479768-B2 | Process for the preparation of amphiphilic imidazolinium compounds | BAYER ANIMAL HEALTH GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-20180148415-A1 | IMPROVED PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148415-A1 | IMPROVED PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-0955999-B1 | NOVEL LIPOSOME COMPLEXES FOR INCREASED SYSTEMIC DELIVERY | US GOV HEALTH & HUMAN SERV (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1047774-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6126965-A | CATIONIC LIPOSOMES OF DIMETHYLDIOCTADECYLAMMONIUM BROMIDE, PHOSPHATIDYLCHOLINE AND CHOLESTEROL WITH ENCAPSULATION | GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE (US) | 2000-10-03 | — | — | US | disclosed |
| US-6120799-A | Cationic lipid compositions targeting angiogenic endothelial cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-09-19 | — | — | US | disclosed |
| WO-1999036514-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE (US) | 1999-07-22 | — | — | WO | disclosed |
| US-5837283-A | Cationic lipid compositions targeting angiogenic endothelial cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479768-B2 | Process for the preparation of amphiphilic imidazolinium compounds | IPO8, IPO9, IPO7 | PRKCE 2145/4885PRKCQ 1672/4885PRKCD 1626/4885 |
| US-20030166601-A1 | Novel colloid synthetic vectors for gene therapy | FUS, HNRNPUL2, HNRNPH1 | PRKCE 4023/4885PRKCQ 3838/4885PRKCD 3781/4885 |
| US-20180148415-A1 | IMPROVED PROCESS FOR THE PREPARATION OF AMPHIPHILIC IMIDAZOLINIUM COMPOUNDS | IPO8, IPO9, IPO7 | PRKCE 2474/4885PRKCQ 1828/4885PRKCD 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.